Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1

Interventions

Filgrastim 9Cyclophosphamide 9X-Rays 7Phantoms, Imaging 7Specimen Handling 6Magnetic Resonance Spectroscopy 6Flow Cytometry 6Carboplatin 6Temozolomide 5Nuclear Medicine Department, Hospital 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Busulfan 5Biopsy 5Therapeutics 4Polymerase Chain Reaction 4Peripheral Blood Stem Cell Transplantation 4Etoposide 4Amplified Fragment Length Polymorphism Analysis 4fludarabine 3Vincristine 3Topotecan 3Thiotepa 3Stem Cell Transplantation 3Psychiatric Rehabilitation 3Methylprednisolone 3Itraconazole 3Irinotecan 3Ipilimumab 3Immunologic Techniques 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Pharmacogenomic Variants × Genitourinary × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡